Scholar Rock gets first FDA nod for rare muscle-wasting disease | Reuters

Scholar Rock receives first FDA approval for rare muscle-wasting disease therapy

The FDA approved Scholar Rock's therapy to treat a rare genetic condition causing muscle weakness, marking the first regulatory approval for the company and the first treatment for this specific disease.